EUCTR2009-012544-16-HU进行中（未招募）不适用
A phase III, randomized, comparative, open-label study of intravenous iron oligosaccharide (Monofer®) administered by infusions or repeated bolus injections in comparison with oral iron sulphate in inflammatory bowel disease subjects with iron deficiency anaemia - Iron Ologisaccharide to patients with IBD and iron deficiency anaemia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects with a diagnosis of IBD with iron deficiency anaemia will be included if they meet all of the following criteria:
- •1. Men and women, aged more than 18 years.
- •2. Subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the Harvey-Bradshaw index for Crohn’s disease and a Mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis).
- •3. Hb <12.0 g/dL (7.45 mmol/L).
- •4. Transferrin saturation (TfS) <20 %.
- •5. Life expectancy beyond 12 months.
- •6. Willingness to participate after informed consent.
- •(Serum ferritin has been chosen not to be inclusion criteria as the cut-off level is highly dependent upon the disease).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1. Anaemia predominantly caused by other factors than iron deficiency anaemia.
- •2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis).
- •3. Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate).
- •4. Known hypersensitivity to any excipients in the investigational drug products.
- •5. Subjects with a history of multiple allergies.
- •6. Active Intestinal Tuberculosis.
- •7. Active Intestinal amoebic infections.
- •8. Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALT) > 3 times upper limit normal).
- •9. Acute infections (assessed by clinical judgement), supplied with white blood cells (WBC) and C-reactive protein (CRP)).
- •10. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- •11. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal, surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches.
- •12. Extensive active bleeding necessitating blood transfusion.
- •13. Planned elective surgery during the study.
- •14. Participation in any other clinical study within 3 months prior to screening.
- •15. Intolerance to oral iron treatment.
- •16. Untreated B12 or folate deficiency.
- •17. Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
- •18. Erythrypoietin treatment within 8 weeks prior to screening visit.
- •19. Diagnosis of Hepatitis B and/or C, confirmed by appropriate lab test.
- •20. Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
- •21. History of immunocompromise, including positive HIV test result.
研究者
相似试验
进行中（未招募）
1 期
A phase III, randomized, comparative, open-label study of intravenous iron oligosaccharide (Monofer®) administered by infusions or repeated bolus injections in comparison with oral iron sulphate in inflammatory bowel disease subjects with iron deficiency anaemia - P-Monofer-IBD-01Inflammatory bowel disease subjects with iron deficiency anaemiaMedDRA version: 9.1 Level: LLT Classification code 10022972 Term: Iron Deficiency anaemiaMedDRA version: 9.1 Level: LLT Classification code 10021972 Term: Inflammatory bowel diseaseEUCTR2009-012544-16-GBPharmacosmos A/S350
进行中（未招募）
不适用
A phase III, randomized, comparative, open-label study of intravenous ironoligosaccharide (Monofer®) administered by infusions or repeated bolusinjections in comparison with oral iron sulphate in inflammatory boweldisease subjects with iron deficiency anaemia - Iron Oligosaccharide to patients with IBD and iron deficiency anaemiaEUCTR2009-012544-16-ATPharmacosmos A/S350
已完成
3 期
Research Study to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (IBD), evaluated as the ability to increase haemoglobin (Hb).CTRI/2009/091/000983Pharmacosmos AS350
进行中（未招募）
不适用
A phase III, randomized, comparative, open-label study of intravenous ironoligosaccharide (Monofer®) administered by infusions or repeated bolusinjections in comparison with oral iron sulphate in inflammatory boweldisease subjects with iron deficiency anaemia - Iron Oligosaccharide to patients with IBD and iron deficiency anaemiaEUCTR2009-012544-16-DKPharmacosmos A/S350
进行中（未招募）
不适用
A Phase III study where Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections is compared with Iron Sulphate taken by mouth in subjects with non-dialysis dependent chronic kidney disease and with renal-related anaemia.on-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: LLTClassification code 10022974Term: Iron deficiency anemiaSystem Organ Class: 100000004851EUCTR2009-016728-29-ATPharmacosmos A/S350